Evidence map›Paper›PMID 22400915›Full record

ArticleAntioxidants & redox signaling2012

Targeted deletion of nrf2 impairs lung development and oxidant injury in neonatal mice.

Hye-Youn Cho, Bennett van Houten, Xuting Wang, Laura Miller-DeGraff, Jennifer Fostel, Wesley Gladwell, Ligon Perrow, Vijayalakshmi Panduri, Lester Kobzik, Masayuki Yamamoto and 2 more

Abstract read
In one paragraph

Article in Antioxidants & redox signaling, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Article
  3. Selenium and Selenoproteins in Neutrophil Functions.Biological trace element research · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Microbial-induced Redox Imbalance in the Neonatal Lung Is Ameliorated by Live Biotherapeutics.American journal of respiratory cell and molecular biology · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. The beginning of GPX2 and 30 years later.Free radical biology & medicine · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Hye-Youn ChoLaboratory of Respiratory Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA. cho2@niehs.nih.gov
Bennett van Houten
Xuting Wang
Laura Miller-DeGraff
Jennifer Fostel
Wesley Gladwell
Ligon Perrow
Vijayalakshmi Panduri
Lester Kobzik
Masayuki Yamamoto
Douglas A Bell
Steven R Kleeberger
National Institutes of Health · USNational Institute of Environmental Health Sciences · USTohoku University · JP

Funding

Gene Expression and MicroarraysZICES102445 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GERRISH, KEVIN · 2009 to 2025
$31.6M
Discovery And Functional Genomics Of Environmental Response GenesZIAES100475 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI BELL, DOUGLAS · 2009 to 2025
$24.4M
The Role Of Nrf2 In Susceptibility To Hyperoxic Lung InjuryZIAES100513 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI KLEEBERGER, STEVEN R · 2009 to 2021
$11.5M
Intramural NIH HHS
6 · The paper itself

Abstract

aimsNrf2 is an essential transcription factor for protection against oxidant disorders. However, its role in organ development and neonatal disease has received little attention. Therapeutically administered oxygen has been considered to contribute to bronchopulmonary dysplasia (BPD) in prematurity. The current study was performed to determine Nrf2-mediated molecular events during saccular-to-alveolar lung maturation, and the role of Nrf2 in the pathogenesis of hyperoxic lung injury using newborn Nrf2-deficient (Nrf2(-/-)) and wild-type (Nrf2(+/+)) mice.

resultsPulmonary basal expression of cell cycle, redox balance, and lipid/carbohydrate metabolism genes was lower while lymphocyte immunity genes were more highly expressed in Nrf2(-/-) neonates than in Nrf2(+/+) neonates. Hyperoxia-induced phenotypes, including mortality, arrest of saccular-to-alveolar transition, and lung edema, and inflammation accompanying DNA damage and tissue oxidation were significantly more severe in Nrf2(-/-) neonates than in Nrf2(+/+) neonates. During lung injury pathogenesis, Nrf2 orchestrated expression of lung genes involved in organ injury and morphology, cellular growth/proliferation, vasculature development, immune response, and cell-cell interaction. Bioinformatic identification of Nrf2 binding motifs and augmented hyperoxia-induced inflammation in genetically deficient neonates supported Gpx2 and Marco as Nrf2 effectors. INNOVATION: This investigation used lung transcriptomics and gene targeted mice to identify novel molecular events during saccular-to-alveolar stage transition and to elucidate Nrf2 downstream mechanisms in protection from hyperoxia-induced injury in neonate mouse lungs.

conclusionNrf2 deficiency augmented lung injury and arrest of alveolarization caused by hyperoxia during the newborn period. Results suggest a therapeutic potential of specific Nrf2 activators for oxidative stress-associated neonatal disorders including BPD.

Indexed as

Gene DeletionAnimalsAnimals, NewbornGlutathione PeroxidaseHyperoxiaLungMiceMice, Inbred C57BLMice, Inbred ICRMice, KnockoutNF-E2-Related Factor 2Oxidative StressPhenotypeGlutathione PeroxidaseGpx2 protein, mouseNfe2l2 protein, mouseNF-E2-Related Factor 2

Identifiers

PMID22400915
PMCPMC3423869
OpenAlexW2028608472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.